Effects of Platelet-activating Factor and Its Differential Regulation by Androgens and Steroid Hormones in Prostate Cancers

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Aug 17

PMID 23949154

Citations 13

Authors

B Xu

L Gao

L Wang

G Tang

M He

Y Yu

X Ni

Y Sun

Affiliations

Soon will be listed here.

Abstract

Background: Platelet-activating factor (PAF) is an arachidonic acid metabolite that plays an important role in cell proliferation, migration and neoangiogenesis, but whether it is involved in the progression of prostate cancer remains undiscovered.

Methods: Clinical prostate specimens were investigated with immunohistochemistry method and in vitro cell experiments referred to MTS cell proliferation assay, invasion and migration experiment, quantitative real-time RT-PCR assay, western blotting analysis and ELISA assay.

Results: Platelet-activating factor synthetase, lyso-PAF acetyl transferase (LPCAT1), increased significantly in castration-resistant prostate cancer (CRPC) specimens and CRPC PC-3 cells than that in controls. Intriguingly, PAF induced invasion and migration of PC-3 cells but not LNCaP cells. The PAF receptor antagonist inhibited proliferation of LNCaP and PC-3 cells. Dihydrotestosterone (DHT) treatment caused a decrease in LPCAT1 expression and PAF release in LNCaP cells, which could be blocked by androgen receptor antagonists. Finally, DHT increased LPCAT1 expression and PAF release in PC-3 cells in a Wnt/β-catenin-dependent manner.

Conclusion: For the first time, our data supported that PAF might play pivotal roles in the progression of prostate cancer, which might throw a new light on the treatment of prostate cancer and the prevention of the emergence of CRPC.

Citing Articles

Impact of targeting the platelet-activating factor and its receptor in cancer treatment.

Qaderi K, Shahmoradi A, Thyagarajan A, Sahu R Mil Med Res. 2025; 12(1):10.

PMID: 40033370 PMC: 11877967. DOI: 10.1186/s40779-025-00597-0.

Clinical Values of Serum Platelet-Activating Factor in Hypertensive Disorders Complicating Pregnancy.

Liu S, Lan Q, Li W, Zhang J, Fu L, Xu Y Kidney Blood Press Res. 2025; 50(1):151-160.

PMID: 39778544 PMC: 11844695. DOI: 10.1159/000543242.

Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways.

Liu Y, Yang C, Zhang Z, Jiang H Front Oncol. 2021; 11:679712.

PMID: 34221998 PMC: 8249243. DOI: 10.3389/fonc.2021.679712.

Lipid Metabolism in Oncology: Why It Matters, How to Research, and How to Treat.

Matsushita Y, Nakagawa H, Koike K Cancers (Basel). 2021; 13(3).

PMID: 33530546 PMC: 7865757. DOI: 10.3390/cancers13030474.

LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.

Han C, Yu G, Mao Y, Song S, Li L, Zhou L PLoS One. 2020; 15(11):e0240801.

PMID: 33137125 PMC: 7605678. DOI: 10.1371/journal.pone.0240801.

References

Jain S, Chakraborty G, Raja R, Kale S, Kundu G . Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res. 2008; 68(19):7750-9. DOI: 10.1158/0008-5472.CAN-07-6689. View

McKiernan J, Benson M . Predicting the clinical course of prostate cancer. J Clin Invest. 2004; 113(6):806-8. PMC: 362125. DOI: 10.1172/JCI21310. View

Youlyouz I, Magnoux E, Guglielmi L, Denizot Y . Expression of a splice variant of the platelet-activating factor receptor transcript 2 in various human cancer cell lines. Mediators Inflamm. 2002; 11(5):329-31. PMC: 1781672. DOI: 10.1080/09629350210000015755. View

Wang L, Chow K, Wu Y . Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells. Scand J Gastroenterol. 2002; 37(4):467-75. DOI: 10.1080/003655202317316114. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Yu J, Akishita M, Eto M, Koizumi H, Hashimoto R, Ogawa S . Src kinase-mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase. Biochem Biophys Res Commun. 2012; 424(3):538-43. DOI: 10.1016/j.bbrc.2012.06.151. View

Grasso C, Wu Y, Robinson D, Cao X, Dhanasekaran S, Khan A . The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-43. PMC: 3396711. DOI: 10.1038/nature11125. View

Ricke W, McPherson S, Bianco J, Cunha G, Wang Y, Risbridger G . Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J. 2007; 22(5):1512-20. DOI: 10.1096/fj.07-9526com. View

Patel M, Kurek C, Dong Q . The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol. 2008; 179(5):1668-75. DOI: 10.1016/j.juro.2007.12.037. View

10.

Weihua Z, Lathe R, Warner M, Gustafsson J . An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci U S A. 2002; 99(21):13589-94. PMC: 129718. DOI: 10.1073/pnas.162477299. View

11.

Enayetallah A, French R, Grant D . Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol. 2006; 37(3-4):133-41. DOI: 10.1007/s10735-006-9050-9. View

12.

Setlur S, Mertz K, Hoshida Y, Demichelis F, Lupien M, Perner S . Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008; 100(11):815-25. PMC: 3073404. DOI: 10.1093/jnci/djn150. View

13.

Truica C, Byers S, Gelmann E . Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000; 60(17):4709-13. View

14.

Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P . Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 2001; 29(1):23-8. DOI: 10.1007/s002400000148. View

15.

Muguruma K, Komatz Y, Ikeda M, Sugimoto T, Saito K . Platelet-activating factor (PAF) in male reproductive organs of guinea pigs and rats: effect of androgen on PAF in seminal vesicles. Biol Reprod. 1993; 48(2):386-92. DOI: 10.1095/biolreprod48.2.386. View

16.

McPherson S, Ellem S, Risbridger G . Estrogen-regulated development and differentiation of the prostate. Differentiation. 2008; 76(6):660-70. DOI: 10.1111/j.1432-0436.2008.00291.x. View

17.

Jan C, Chao Y . Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca2+ levels and growth of human prostate cancer cells. Cell Signal. 2004; 16(8):959-65. DOI: 10.1016/j.cellsig.2004.01.011. View

18.

Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G . PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol. 2000; 157(5):1713-25. PMC: 1885724. DOI: 10.1016/S0002-9440(10)64808-0. View

19.

Dreicer R, Gleave M, Kibel A, Thrasher J, Moul J . Targeting the androgen receptor--theory and practice. Urology. 2011; 78(5 Suppl):S482-4. DOI: 10.1016/j.urology.2011.05.052. View

20.

Xu B, Sun Y, Tang G, Xu C, Wang L, Zhang Y . Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor. Cancer Lett. 2009; 278(2):220-229. DOI: 10.1016/j.canlet.2009.01.007. View